First Manhattan
IRD

First Manhattan’s Opus Genetics IRD Stock Holding History

First Manhattan’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-600
Closed -$2.12K – 1723
2022
Q4 		$2.12K Hold
600
– – ﹤0.01% 1531
2022
Q3 		$1K Hold
600
– – ﹤0.01% 1495
2022
Q2 		$1K Hold
600
– – ﹤0.01% 1521
2022
Q1 		$1K Hold
600
– – ﹤0.01% 1566
2021
Q4 		$2K Hold
600
– – ﹤0.01% 1496
2021
Q3 		$3K Hold
600
– – ﹤0.01% 1503
2021
Q2 		$3K Hold
600
– – ﹤0.01% 1488
2021
Q1 		$3K Buy
+600
New +$5.58K ﹤0.01% 1411

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

First Manhattan's IRD Position: Q1 2023 in Review

First Manhattan sold out of Opus Genetics (IRD) in Q1 2023, closing a stake of 600 shares — an estimated $2.12K sold.

First Manhattan first reported a position in IRD in Q1 2021 and held it in 8 quarters. The position peaked at $3K in Q3 2021. 41 funds tracked by Wall St. Rank hold IRD as of Q1 2023.

  • First Manhattan reported no remaining Opus Genetics position as of Q1 2023 after selling out during the quarter.
  • First Manhattan sold 600 Opus Genetics shares in Q1 2023, an estimated $2.12K.
  • First Manhattan first reported a position in Opus Genetics in Q1 2021 and held it in 8 quarters.
  • First Manhattan's Opus Genetics position peaked at $3K in Q3 2021.
  • 41 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2023.

Based on First Manhattan's 13F filing for Q1 2023, filed 15 May 2023.